Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 91

1.

The replication initiation determinant protein (RepID) modulates replication by recruiting CUL4 to chromatin.

Jang SM, Zhang Y, Utani K, Fu H, Redon CE, Marks AB, Smith OK, Redmond CJ, Baris AM, Tulchinsky DA, Aladjem MI.

Nat Commun. 2018 Jul 17;9(1):2782. doi: 10.1038/s41467-018-05177-6.

PMID:
30018425
2.

Chromatin-Bound Cullin-Ring Ligases: Regulatory Roles in DNA Replication and Potential Targeting for Cancer Therapy.

Jang SM, Redon CE, Aladjem MI.

Front Mol Biosci. 2018 Mar 13;5:19. doi: 10.3389/fmolb.2018.00019. eCollection 2018. Review.

3.

A systematic review of gallstone sigmoid ileus management.

Farkas N, Kaur V, Shanmuganandan A, Black J, Redon C, Frampton AE, West N.

Ann Med Surg (Lond). 2018 Jan 31;27:32-39. doi: 10.1016/j.amsu.2018.01.004. eCollection 2018 Mar. Review.

4.

Phase I trial of belinostat with cisplatin and etoposide in advanced solid tumors, with a focus on neuroendocrine and small cell cancers of the lung.

Balasubramaniam S, Redon CE, Peer CJ, Bryla C, Lee MJ, Trepel JB, Tomita Y, Rajan A, Giaccone G, Bonner WM, Figg WD, Fojo T, Piekarz RL, Bates SE.

Anticancer Drugs. 2018 Jun;29(5):457-465. doi: 10.1097/CAD.0000000000000596.

PMID:
29420340
5.

SLFN11 Blocks Stressed Replication Forks Independently of ATR.

Murai J, Tang SW, Leo E, Baechler SA, Redon CE, Zhang H, Al Abo M, Rajapakse VN, Nakamura E, Jenkins LMM, Aladjem MI, Pommier Y.

Mol Cell. 2018 Feb 1;69(3):371-384.e6. doi: 10.1016/j.molcel.2018.01.012.

PMID:
29395061
6.

Phase I Study of ATR Inhibitor M6620 in Combination With Topotecan in Patients With Advanced Solid Tumors.

Thomas A, Redon CE, Sciuto L, Padiernos E, Ji J, Lee MJ, Yuno A, Lee S, Zhang Y, Tran L, Yutzy W, Rajan A, Guha U, Chen H, Hassan R, Alewine CC, Szabo E, Bates SE, Kinders RJ, Steinberg SM, Doroshow JH, Aladjem MI, Trepel JB, Pommier Y.

J Clin Oncol. 2018 Jun 1;36(16):1594-1602. doi: 10.1200/JCO.2017.76.6915. Epub 2017 Dec 18.

PMID:
29252124
7.

Design and Synthesis of Chlorinated and Fluorinated 7-Azaindenoisoquinolines as Potent Cytotoxic Anticancer Agents That Inhibit Topoisomerase I.

Elsayed MSA, Su Y, Wang P, Sethi T, Agama K, Ravji A, Redon CE, Kiselev E, Horzmann KA, Freeman JL, Pommier Y, Cushman M.

J Med Chem. 2017 Jul 13;60(13):5364-5376. doi: 10.1021/acs.jmedchem.6b01870. Epub 2017 Jun 28.

PMID:
28657311
8.

Phosphorylated SIRT1 associates with replication origins to prevent excess replication initiation and preserve genomic stability.

Utani K, Fu H, Jang SM, Marks AB, Smith OK, Zhang Y, Redon CE, Shimizu N, Aladjem MI.

Nucleic Acids Res. 2017 Jul 27;45(13):7807-7824. doi: 10.1093/nar/gkx468.

9.

Histone variant H2A.J accumulates in senescent cells and promotes inflammatory gene expression.

Contrepois K, Coudereau C, Benayoun BA, Schuler N, Roux PF, Bischof O, Courbeyrette R, Carvalho C, Thuret JY, Ma Z, Derbois C, Nevers MC, Volland H, Redon CE, Bonner WM, Deleuze JF, Wiel C, Bernard D, Snyder MP, Rübe CE, Olaso R, Fenaille F, Mann C.

Nat Commun. 2017 May 10;8:14995. doi: 10.1038/ncomms14995.

10.

Synthesis and Biological Evaluation of the First Triple Inhibitors of Human Topoisomerase 1, Tyrosyl-DNA Phosphodiesterase 1 (Tdp1), and Tyrosyl-DNA Phosphodiesterase 2 (Tdp2).

Wang P, Elsayed MSA, Plescia CB, Ravji A, Redon CE, Kiselev E, Marchand C, Zeleznik O, Agama K, Pommier Y, Cushman M.

J Med Chem. 2017 Apr 27;60(8):3275-3288. doi: 10.1021/acs.jmedchem.6b01565. Epub 2017 Apr 18.

PMID:
28418653
11.

The Causal Relationship between DNA Damage Induction in Bovine Lymphocytes and the Fukushima Nuclear Power Plant Accident.

Nakamura AJ, Suzuki M, Redon CE, Kuwahara Y, Yamashiro H, Abe Y, Takahashi S, Fukuda T, Isogai E, Bonner WM, Fukumoto M.

Radiat Res. 2017 May;187(5):630-636. doi: 10.1667/RR14630.1. Epub 2017 Feb 27.

12.

Phosphorylated fraction of H2AX as a measurement for DNA damage in cancer cells and potential applications of a novel assay.

Ji J, Zhang Y, Redon CE, Reinhold WC, Chen AP, Fogli LK, Holbeck SL, Parchment RE, Hollingshead M, Tomaszewski JE, Dudon Q, Pommier Y, Doroshow JH, Bonner WM.

PLoS One. 2017 Feb 3;12(2):e0171582. doi: 10.1371/journal.pone.0171582. eCollection 2017.

13.

Order from clutter: selective interactions at mammalian replication origins.

Aladjem MI, Redon CE.

Nat Rev Genet. 2017 Feb;18(2):101-116. doi: 10.1038/nrg.2016.141. Epub 2016 Nov 21. Review.

PMID:
27867195
14.

Evaluation of surrogate tissues as indicators of drug activity in a melanoma skin model.

Parekh PR, Choudhuri R, Weyemi U, Martin OA, Bonner WM, Redon CE.

Cancer Med. 2016 Aug;5(8):1731-41. doi: 10.1002/cam4.726. Epub 2016 Jun 23.

15.

Twist1 and Slug mediate H2AX-regulated epithelial-mesenchymal transition in breast cells.

Weyemi U, Redon CE, Sethi TK, Burrell AS, Jailwala P, Kasoji M, Abrams N, Merchant A, Bonner WM.

Cell Cycle. 2016 Sep 16;15(18):2398-404. doi: 10.1080/15384101.2016.1198864. Epub 2016 Jun 17.

16.

A replicator-specific binding protein essential for site-specific initiation of DNA replication in mammalian cells.

Zhang Y, Huang L, Fu H, Smith OK, Lin CM, Utani K, Rao M, Reinhold WC, Redon CE, Ryan M, Kim R, You Y, Hanna H, Boisclair Y, Long Q, Aladjem MI.

Nat Commun. 2016 Jun 8;7:11748. doi: 10.1038/ncomms11748.

17.

Clinical and pharmacologic evaluation of two dosing schedules of indotecan (LMP400), a novel indenoisoquinoline, in patients with advanced solid tumors.

Kummar S, Chen A, Gutierrez M, Pfister TD, Wang L, Redon C, Bonner WM, Yutzy W, Zhang Y, Kinders RJ, Ji J, Allen D, Covey JM, Eiseman JL, Holleran JL, Beumer JH, Rubinstein L, Collins J, Tomaszewski J, Parchment R, Pommier Y, Doroshow JH.

Cancer Chemother Pharmacol. 2016 Jul;78(1):73-81. doi: 10.1007/s00280-016-2998-6. Epub 2016 May 11.

18.

Effects of Breast Shielding during Heart Imaging on DNA Double-Strand-Break Levels: A Prospective Randomized Controlled Trial.

Cheezum MK, Redon CE, Burrell AS, Kaviratne AS, Bindeman J, Maeda D, Balmakhtar H, Pezel A, Wisniewski P, Delacruz P, Nguyen B, Bonner WM, Villines TC.

Radiology. 2016 Oct;281(1):62-71. doi: 10.1148/radiol.2016152301. Epub 2016 Apr 15.

19.

H2AX and EMT: deciphering beyond DNA repair.

Weyemi U, Redon CE, Bonner WM.

Cell Cycle. 2016 May 18;15(10):1305-6. doi: 10.1080/15384101.2016.1160659. Epub 2016 Mar 17. No abstract available.

20.

The histone variant H2A.X is a regulator of the epithelial-mesenchymal transition.

Weyemi U, Redon CE, Choudhuri R, Aziz T, Maeda D, Boufraqech M, Parekh PR, Sethi TK, Kasoji M, Abrams N, Merchant A, Rajapakse VN, Bonner WM.

Nat Commun. 2016 Feb 15;7:10711. doi: 10.1038/ncomms10711.

21.

90Y-daclizumab, an anti-CD25 monoclonal antibody, provided responses in 50% of patients with relapsed Hodgkin's lymphoma.

Janik JE, Morris JC, O'Mahony D, Pittaluga S, Jaffe ES, Redon CE, Bonner WM, Brechbiel MW, Paik CH, Whatley M, Chen C, Lee JH, Fleisher TA, Brown M, White JD, Stewart DM, Fioravanti S, Lee CC, Goldman CK, Bryant BR, Junghans RP, Carrasquillo JA, Worthy T, Corcoran E, Conlon KC, Waldmann TA.

Proc Natl Acad Sci U S A. 2015 Oct 20;112(42):13045-50. doi: 10.1073/pnas.1516107112. Epub 2015 Oct 5.

22.

Inactivation of NADPH oxidases NOX4 and NOX5 protects human primary fibroblasts from ionizing radiation-induced DNA damage.

Weyemi U, Redon CE, Aziz T, Choudhuri R, Maeda D, Parekh PR, Bonner MY, Arbiser JL, Bonner WM.

Radiat Res. 2015 Mar;183(3):262-70. doi: 10.1667/RR13799.1. Epub 2015 Feb 23.

23.

NADPH oxidase 4 is a critical mediator in Ataxia telangiectasia disease.

Weyemi U, Redon CE, Aziz T, Choudhuri R, Maeda D, Parekh PR, Bonner MY, Arbiser JL, Bonner WM.

Proc Natl Acad Sci U S A. 2015 Feb 17;112(7):2121-6. doi: 10.1073/pnas.1418139112. Epub 2015 Feb 2.

24.

A phase i study of DMS612, a novel bifunctional alkylating agent.

Appleman LJ, Balasubramaniam S, Parise RA, Bryla C, Redon CE, Nakamura AJ, Bonner WM, Wright JJ, Piekarz R, Kohler DR, Jiang Y, Belani CP, Eiseman J, Chu E, Beumer JH, Bates SE.

Clin Cancer Res. 2015 Feb 15;21(4):721-9. doi: 10.1158/1078-0432.CCR-14-1333. Epub 2014 Dec 2.

25.

A phase I/II trial of belinostat in combination with cisplatin, doxorubicin, and cyclophosphamide in thymic epithelial tumors: a clinical and translational study.

Thomas A, Rajan A, Szabo E, Tomita Y, Carter CA, Scepura B, Lopez-Chavez A, Lee MJ, Redon CE, Frosch A, Peer CJ, Chen Y, Piekarz R, Steinberg SM, Trepel JB, Figg WD, Schrump DS, Giaccone G.

Clin Cancer Res. 2014 Nov 1;20(21):5392-402. doi: 10.1158/1078-0432.CCR-14-0968. Epub 2014 Sep 4.

26.

Systemic DNA damage accumulation under in vivo tumor growth can be inhibited by the antioxidant Tempol.

Georgakilas AG, Redon CE, Ferguson NF, Kryston TB, Parekh P, Dickey JS, Nakamura AJ, Mitchell JB, Bonner WM, Martin OA.

Cancer Lett. 2014 Oct 28;353(2):248-57. doi: 10.1016/j.canlet.2014.07.030. Epub 2014 Jul 25.

27.

Oxidative DNA damage caused by inflammation may link to stress-induced non-targeted effects.

Sprung CN, Ivashkevich A, Forrester HB, Redon CE, Georgakilas A, Martin OA.

Cancer Lett. 2015 Jan 1;356(1):72-81. doi: 10.1016/j.canlet.2013.09.008. Epub 2013 Sep 14. Review.

28.

Mito-tempol and dexrazoxane exhibit cardioprotective and chemotherapeutic effects through specific protein oxidation and autophagy in a syngeneic breast tumor preclinical model.

Dickey JS, Gonzalez Y, Aryal B, Mog S, Nakamura AJ, Redon CE, Baxa U, Rosen E, Cheng G, Zielonka J, Parekh P, Mason KP, Joseph J, Kalyanaraman B, Bonner W, Herman E, Shacter E, Rao VA.

PLoS One. 2013 Aug 5;8(8):e70575. doi: 10.1371/journal.pone.0070575. Print 2013.

29.

Evaluation of the gamma-H2AX assay for radiation biodosimetry in a swine model.

Moroni M, Maeda D, Whitnall MH, Bonner WM, Redon CE.

Int J Mol Sci. 2013 Jul 8;14(7):14119-35. doi: 10.3390/ijms140714119.

30.

Susceptibility to bystander DNA damage is influenced by replication and transcriptional activity.

Dickey JS, Baird BJ, Redon CE, Avdoshina V, Palchik G, Wu J, Kondratyev A, Bonner WM, Martin OA.

Nucleic Acids Res. 2012 Nov 1;40(20):10274-86. doi: 10.1093/nar/gks795. Epub 2012 Aug 31.

31.

NADPH Oxidases NOXs and DUOXs as putative targets for cancer therapy.

Weyemi U, Redon CE, Parekh PR, Dupuy C, Bonner WM.

Anticancer Agents Med Chem. 2013 Mar;13(3):502-14. Review.

PMID:
22931418
32.

Mitochondrial topoisomerase I is critical for mitochondrial integrity and cellular energy metabolism.

Douarre C, Sourbier C, Dalla Rosa I, Brata Das B, Redon CE, Zhang H, Neckers L, Pommier Y.

PLoS One. 2012;7(7):e41094. doi: 10.1371/journal.pone.0041094. Epub 2012 Jul 20.

33.

γ-H2AX and other histone post-translational modifications in the clinic.

Redon CE, Weyemi U, Parekh PR, Huang D, Burrell AS, Bonner WM.

Biochim Biophys Acta. 2012 Jul;1819(7):743-56. doi: 10.1016/j.bbagrm.2012.02.021. Epub 2012 Mar 9. Review.

34.

SOD2 deficiency promotes aging phenotypes in mouse skin.

Weyemi U, Parekh PR, Redon CE, Bonner WM.

Aging (Albany NY). 2012 Feb;4(2):116-8. Review. No abstract available.

35.

Use of the γ-H2AX assay to monitor DNA damage and repair in translational cancer research.

Ivashkevich A, Redon CE, Nakamura AJ, Martin RF, Martin OA.

Cancer Lett. 2012 Dec 31;327(1-2):123-33. doi: 10.1016/j.canlet.2011.12.025. Epub 2011 Dec 21. Review.

36.

High salt and DNA double-strand breaks.

Redon CE, Bonner WM.

Proc Natl Acad Sci U S A. 2011 Dec 20;108(51):20281-2. doi: 10.1073/pnas.1117713109. Epub 2011 Dec 12. No abstract available.

37.

Q(γ-H2AX), an analysis method for partial-body radiation exposure using γ-H2AX in nonhuman primate lymphocytes.

Redon CE, Nakamura AJ, Gouliaeva K, Rahman A, Blakely WF, Bonner WM.

Radiat Meas. 2011 Sep 1;46(9):877-881.

38.

Systemic DNA damage related to cancer.

Martin OA, Redon CE, Nakamura AJ, Dickey JS, Georgakilas AG, Bonner WM.

Cancer Res. 2011 May 15;71(10):3437-41. doi: 10.1158/0008-5472.CAN-10-4579. Epub 2011 May 10. Review.

39.

Para-inflammation mediates systemic DNA damage in response to tumor growth.

Martin OA, Redon CE, Dickey JS, Nakamura AJ, Bonner WM.

Commun Integr Biol. 2011 Jan;4(1):78-81. doi: 10.4161/cib.4.1.13942.

40.

Recent developments in the use of γ-H2AX as a quantitative DNA double-strand break biomarker.

Redon CE, Nakamura AJ, Martin OA, Parekh PR, Weyemi US, Bonner WM.

Aging (Albany NY). 2011 Feb;3(2):168-74.

41.

γH2AX foci as a measure of DNA damage: a computational approach to automatic analysis.

Ivashkevich AN, Martin OA, Smith AJ, Redon CE, Bonner WM, Martin RF, Lobachevsky PN.

Mutat Res. 2011 Jun 3;711(1-2):49-60. doi: 10.1016/j.mrfmmm.2010.12.015. Epub 2011 Jan 7.

42.

Hypothermia postpones DNA damage repair in irradiated cells and protects against cell killing.

Baird BJ, Dickey JS, Nakamura AJ, Redon CE, Parekh P, Griko YV, Aziz K, Georgakilas AG, Bonner WM, Martin OA.

Mutat Res. 2011 Jun 3;711(1-2):142-9. doi: 10.1016/j.mrfmmm.2010.12.006. Epub 2010 Dec 24.

PMID:
21185842
43.

The use of gamma-H2AX as a biodosimeter for total-body radiation exposure in non-human primates.

Redon CE, Nakamura AJ, Gouliaeva K, Rahman A, Blakely WF, Bonner WM.

PLoS One. 2010 Nov 23;5(11):e15544. doi: 10.1371/journal.pone.0015544.

44.

γ-H2AX detection in peripheral blood lymphocytes, splenocytes, bone marrow, xenografts, and skin.

Redon CE, Nakamura AJ, Sordet O, Dickey JS, Gouliaeva K, Tabb B, Lawrence S, Kinders RJ, Bonner WM, Sedelnikova OA.

Methods Mol Biol. 2011;682:249-70. doi: 10.1007/978-1-60327-409-8_18.

PMID:
21057933
45.

Betahistine treatment improves the recovery of static symptoms in patients with unilateral vestibular loss.

Redon C, Lopez C, Bernard-Demanze L, Dumitrescu M, Magnan J, Lacour M, Borel L.

J Clin Pharmacol. 2011 Apr;51(4):538-48. doi: 10.1177/0091270010369241. Epub 2010 Oct 12.

PMID:
20940335
46.

Tumors induce complex DNA damage in distant proliferative tissues in vivo.

Redon CE, Dickey JS, Nakamura AJ, Kareva IG, Naf D, Nowsheen S, Kryston TB, Bonner WM, Georgakilas AG, Sedelnikova OA.

Proc Natl Acad Sci U S A. 2010 Oct 19;107(42):17992-7. doi: 10.1073/pnas.1008260107. Epub 2010 Sep 20.

47.

Histone gammaH2AX and poly(ADP-ribose) as clinical pharmacodynamic biomarkers.

Redon CE, Nakamura AJ, Zhang YW, Ji JJ, Bonner WM, Kinders RJ, Parchment RE, Doroshow JH, Pommier Y.

Clin Cancer Res. 2010 Sep 15;16(18):4532-42. doi: 10.1158/1078-0432.CCR-10-0523. Epub 2010 Sep 7. Review.

48.

γH2AX: Applications for the evaluation of telomerase-based cancer therapy.

Nakamura AJ, Redon CE, Bonner WM.

Cell Cycle. 2010 Sep 1;9(17):3385-6. doi: 10.4161/cc.9.17.13003. Epub 2010 Sep 13. No abstract available.

PMID:
20703091
49.

Telomere-dependent and telomere-independent origins of endogenous DNA damage in tumor cells.

Nakamura AJ, Redon CE, Bonner WM, Sedelnikova OA.

Aging (Albany NY). 2009 Feb 4;1(2):212-8.

50.

Role of oxidatively induced DNA lesions in human pathogenesis.

Sedelnikova OA, Redon CE, Dickey JS, Nakamura AJ, Georgakilas AG, Bonner WM.

Mutat Res. 2010 Apr-Jun;704(1-3):152-9. doi: 10.1016/j.mrrev.2009.12.005. Epub 2010 Jan 8. Review.

Supplemental Content

Support Center